3. Как не умереть от заболеваний головного мозга

3. Как не умереть от заболеваний головного мозга

^{‹‹1››.} Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.

^{‹‹2››.} Centers for Disease Control and Prevention. Deaths: final data for 2013 table 10. Number of deaths from 113 selected causes. National Vital Statistics Report 2016;64(2).

^{‹‹3››.} Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.

^{‹‹4››.} Grau-Olivares M, Arboix A. Mild cognitive impairment in stroke patients with ischemic cerebral small- vessel disease: a forerunner of vascular dementia? Expert Rev Neurother. 2009; 9(8):1201–17.

^{‹‹5››.} Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ. 2011;343:d6617.

^{‹‹6››.} Aune D, Chan DS, Greenwood DC, et al. Dietary fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies. Ann Oncol. 2012;23(6):1394–402.

^{‹‹7››.} Yao B, Fang H, Xu W, et al. Dietary fiber intake and risk of type 2 diabetes: a dose-response analysis of prospective studies. Eur J Epidemiol. 2014;29(2):79–88.

^{‹‹8››.} Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2013;347:f6879.

^{‹‹9››.} Maskarinec G, Takata Y, Pagano I, et al. Trends and dietary determinants of overweight and obesity in a multiethnic population. Obesity (Silver Spring). 2006;14(4):717–26.

^{‹‹10››.} Kim Y, Je Y. Dietary fiber intake and total mortality: a meta-analysis of prospective cohort studies. Am J Epidemiol. 2014;180(6):565–73.

^{‹‹11››.} Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fiber intake and risk of first stroke: a systematic review and meta-analysis. Stroke. 2013;44(5):1360–8.

^{‹‹12››.} Clemens R, Kranz S, Mobley AR, et al. Filling America’s fiber intake gap: summary of a roundtable to probe realistic solutions with a focus on grain-based foods. J Nutr. 2012;142(7):1390S–401S.

^{‹‹13››.} Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fiber intake and risk of first stroke: a systematic review and meta-analysis. Stroke. 2013;44(5):1360–8.

^{‹‹14››.} Whitehead A, Beck EJ, Tosh S, Wolever TM. Cholesterol-lowering Effects of oat ?-glucan: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100(6):1413–21.

^{‹‹15››.} Silva FM, Kramer CK, De Almeida JC, Steemburgo T, Gross JL, Azevedo MJ. Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with metaanalysis of randomized controlled trials. Nutr Rev. 2013;71(12):790–801.

^{‹‹16››.} Streppel MT, Arends LR, van ’t Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med. 2005; 165(2):150–6.

^{‹‹17››.} Centers for Disease Control and Prevention. Deaths: final data for 2013 table 10. Number of deaths from 113 selected causes. National Vital Statistics Report 2016;64(2).

^{‹‹18››.} van de Laar RJ, Stehouwer CDA, van Bussel BCT, et al. Lower lifetime dietary fiber intake is associated with carotid artery stiffness: the Amsterdam Growth and Health Longitudinal Study. Am J Clin Nutr. 2012;96(1):14–23.

^{‹‹19››.} van de Laar RJ, Stehouwer CDA, van Bussel BCT, et al. Lower lifetime dietary fiber intake is associated with carotid artery stiffness: the Amsterdam Growth and Health Longitudinal Study. Am J Clin Nutr. 2012;96(1):14–23.

^{‹‹20››.} Casiglia E, Tikhonoff V, Caffi S, et al. High dietary fiber intake prevents stroke at a population level. Clin Nutr. 2013;32(5):811–8.

^{‹‹21››.} Tikhonoff V, Palatini P, Casiglia E. Letter by Tikhonoff et al regarding article, «Dietary fiber intake and risk of first stroke: a systematic review and meta-analysis,» Stroke. 2013; 44(9): e109.

^{‹‹22››.} Threapleton DE, Greenwood DC, Burley VJ. Response to letter regarding article, «Dietary fiber intake and risk of first stroke: a systematic review and meta-analysis,» Stroke. 2013; 44(9):e110.

^{‹‹23››.} Eaton SB, Konner M. Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med. 1985;312(5):283–9.

^{‹‹24››.} Cogswell ME, Zhang Z, Carriquiry AL, et al. Sodium and potassium intakes among US adults: NHANES 2003–2008. Am J Clin Nutr. 2012;96(3):647–57.

^{‹‹25››.} Cogswell ME, Zhang Z, Carriquiry AL, et al. Sodium and potassium intakes among US adults: NHANES 2003–2008. Am J Clin Nutr. 2012;96(3):647–57.

^{‹‹26››.} D’Elia L, Barba G, Cappuccio FP, et al. Potassium intake, stroke, and cardiovascular disease a meta- analysis of prospective studies. J Am Coll Cardiol. 2011;57(10):1210–9.

^{‹‹27››.} U.S. Department of Agriculture. USDA National Nutrient Database for Standard Reference. http://ndb. nal.usda.gov/ndb/nutrients/index?fg=& nutrient1=306&nutrient2=&nutrient3=&subset=0&sort=c&totC ount=0&offset=0&measureby=g. 2011. Accessed April 1, 2015.

^{‹‹28››.} U.S. Department of Agriculture Dietary Guidelines for Americans 2005. Appendix B-1. Food sources of potassium. http://www.health.gov/dietaryguidelines/dga2005/document/html/appendixb.htm. July 9, 2008. Accessed May 1, 2015.

^{‹‹29››.} Hu D, Huang J, Wang Y, Zhang D, Qu Y. Fruits and vegetables consumption and risk of stroke: a meta- analysis of prospective cohort studies. Stroke. 2014;45(6):1613–9.

^{‹‹30››.} Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular protective Effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr. 2011;93(1):73–80.

^{‹‹31››.} Takumi H, Nakamura H, Simizu T, et al. Bioavailability of orally administered water-dispersible hesperetin and its Effect on peripheral vasodilatation in human subjects: implication of endothelial functions of plasma conjugated metabolites. Food Funct. 2012;3(4):389–98.

^{‹‹32››.} Patyar S, Patyar RR. Correlation between sleep duration and risk of stroke. J Stroke Cerebrovasc Dis. 2015;24(5):905–11.

^{‹‹33››.} Ikehara S, Iso H, Date C, et al; JACC Study Group. Association of sleep duration with mortality from cardiovascular disease and other causes for Japanese men and women: the JACC study. Sleep. 2009;32(3):295–301.

^{‹‹34››.} Fang J, Wheaton AG, Ayala C. Sleep duration and history of stroke among adults from the USA. J Sleep Res. 2014;23(5):531–7.

^{‹‹35››.} von Ruesten A, Weikert C, Fietze I, et al. Association of sleep duration with chronic diseases in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. PloS ONE. 2012;7(1):e30972.

^{‹‹36››.} Pan A, De Silva DA, Yuan JM, et al. Sleep duration and risk of stroke mortality among Chinese adults: Singapore Chinese health study. Stroke. 2014;45(6):1620–5.

^{‹‹37››.} Leng Y, Cappuccio FP, Wainwright NW, et al. Sleep duration and risk of fatal and nonfatal stroke: a prospective study and meta-analysis. Neurology. 2015;84(11):1072–9.

^{‹‹38››.} Sansevero TB. The Profit Machine. Madrid: Cultiva Libros. 2009;59.

^{‹‹39››.} Harman D. The biologic clock: the mitochondria? J Am Geriatr Soc. 1972;20(4):145–7.

^{‹‹40››.} Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979;59(3):527–605.

^{‹‹41››.} Emerit I. Reactive oxygen species, chromosome mutation, and cancer: possible role of clastogenic factors in carcinogenesis. Free Radic Biol Med. 1994;16(1):99–109.

^{‹‹42››.} Rautiainen S, Larsson S, Virtamo J, et al. Total antioxidant capacity of diet and risk of stroke: a population-based prospective cohort of women. Stroke. 2012;43(2):335–40.

^{‹‹43››.} Del Rio D, Agnoli C, Pellegrini N, et al. Total antioxidant capacity of the diet is associated with lower risk of ischemic stroke in a large Italian cohort. J Nutr. 2011;141(1):118–23.

^{‹‹44››.} Satia JA, Littman A, Slatore CG, Galanko JA, White E. Long-term use of beta-carotene, retinol, lycopene, and lutein supplements and lung cancer risk: results from the VITamins And Lifestyle (VITAL) study. Am J Epidemiol. 2009;169(7):815–28.

^{‹‹45››.} Hankey GJ. Vitamin supplementation and stroke prevention. Stroke. 2012;43(10):2814–8.

^{‹‹46››.} Carlsen MH, Halvorsen BL, Holte K, et al. The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutr J. 2010 Jan 22;9:3.

^{‹‹47››.} Yang M, Chung SJ, Chung CE, et al. Estimation of total antioxidant capacity from diet and supplements in US adults. Br J Nutr. 2011;106(2):254–63.

^{‹‹48››.} Carlsen MH, Halvorsen BL, Holte K, et al. The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutr J. 2010 Jan 22;9:3.

^{‹‹49››.} Bastin S, Henken K. Water Content of Fruits and Vegetables. ENRI-129. University of Kentucky College of Agriculture Cooperative Extension Service. http://www2.ca.uky.edu/enri/pubs/enri129.pdf. December 1997. Accessed March 3, 2015.

^{‹‹50››.} Carlsen MH, Halvorsen BL, Holte K, et al. The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutr J. 2010 Jan 22;9:3.

^{‹‹51››.} Carlsen MH, Halvorsen BL, Holte K, et al. The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutr J. 2010 Jan 22;9:3.

^{‹‹52››.} Kelly PJ, Morrow JD, Ning M, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke. 2008;39(1):100–4.

^{‹‹53››.} Lilamand M, Kelaiditi E, Guyonnet S, et al. Flavonoids and arterial stiffness: promising perspectives. Nutr Metab Cardiovasc Dis. 2014;24(7):698–704.

^{‹‹54››.} Santhakumar AB, Bulmer AC, Singh I. A review of the mechanisms and Effectiveness of dietary polyphenols in reducing oxidative stress and thrombotic risk. J Hum Nutr Diet. 2014;27(1): 1–21.

^{‹‹55››.} Stoclet JC, Chataigneau T, Ndiaye M, et al. Vascular protection by dietary polyphenols. Eur J Pharmacol. 2004;500(1–3):299–313.

^{‹‹56››.} Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress?. Neurosci Biobehav Rev. 2014;45:46–62.

^{‹‹57››.} Watzl B. Anti-inflammatory effects of plant-based foods and of their constituents. Int J Vitam Nutr Res. 2008;78(6):293–8.

^{‹‹58››.} Franzini L, Ardigi D, Valtue?a S, et al. Food selection based on high total antioxidant capacity improves endothelial function in a low cardiovascular risk population. Nutr Metab Cardiovasc Dis. 2012;22(1):50–7.

^{‹‹59››.} Alzheimer’s Association factsheet. http://www.alz.org/documents_custom/2013_facts_figures_fact_sheet.pdf. March 2013. Accessed April 3, 2015.

^{‹‹60››.} de la Torre JC. A turning point for Alzheimer’s disease? Biofactors. 2012;38(2):78–83.

^{‹‹61››.} de la Torre JC. Alzheimer’s disease is incurable but preventable. J Alzheimers Dis. 2010; 20(3):861–70.

^{‹‹62››.} Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–28.

^{‹‹63››.} Singh-Manoux A, Kivimaki M, Glymour MM, et al. Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ. 2012;344:d7622.

^{‹‹64››.} Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44.

^{‹‹65››.} Barnard ND, Bush AI, Ceccarelli A, et al. Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol Aging. 2014;35 Suppl 2:S74–8.

^{‹‹66››.} Ramirez-Bermudez J. Alzheimer’s disease: critical notes on the history of a medical concept. Arch Med Res. 2012;43(8):595–9.

^{‹‹67››.} Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, «?ber eine eigenartige Erkankung der Hirnrinde.» Clin Anat. 1995; 8(6):429–31.

^{‹‹68››.} Kovacic JC, Fuster V. Atherosclerotic risk factors, vascular cognitive impairment, and Alzheimer disease. Mt Sinai J Med. 2012;79:664–73.

^{‹‹69››.} Cardiogenic Dementia. Lancet. 1977;1(8001):27–8.

^{‹‹70››.} Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44.

^{‹‹71››.} Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44.

^{‹‹72››.} Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(Pt 12):3749–56.

^{‹‹73››.} Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology. 2005;64(3):494–500.

^{‹‹74››.} de la Torre JC. Vascular risk factors: a ticking time bomb to Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2013;28(6):551–9.

^{‹‹75››.} Roher AE, Tyas SL, Maarouf CL, et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement. 2011;7(4):436–44.

^{‹‹76››.} de la Torre JC. Vascular basis of Alzheimer’s pathogenesis. Ann N Y Acad Sci. 2002;977:196–215.

^{‹‹77››.} Zhu J, Wang Y, Li J, et al. Intracranial artery stenosis and progression from mild cognitive impairment to Alzheimer disease. Neurology. 2014;82(10):842–9.

^{‹‹78››.} Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009;73(9):674–80.

^{‹‹79››.} Mizuno T, Nakata M, Naiki H, et al. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J Biol Chem. 1999;274(21):15110–4.

^{‹‹80››.} Trumbo PR, Shimakawa T. Tolerable upper intake levels for trans fat, saturated fat, and cholesterol. Nutr Rev. 2011;69(5):270–8.

^{‹‹81››.} Benjamin MM, Roberts WC. Facts and principles learned at the 39th Annual Williamsburg Conference on Heart Disease. Proc (Bayl Univ Med Cent). 2013;26(2):124–36.

^{‹‹82››.} Corsinovi L, Biasi F, Poli G, et al. Dietary lipids and their oxidized products in Alzheimer’s disease. Mol Nutr Food Res. 2011;55 Suppl 2:S161–72.

^{‹‹83››.} Harris JR, Milton NGN. Cholesterol in Alzheimer’s disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47–75.

^{‹‹84››.} Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci. 2003;6(4):345–51.

^{‹‹85››.} Harris JR, Milton NGN. Cholesterol in Alzheimer’s disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47–75.

^{‹‹86››.} Reed B, Villeneuve S, Mack W, et al. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014;71(2):195–200.

^{‹‹87››.} US Food and Drug Administration. Important safety label changes to cholesterol-lowering statin drugs. Silver Spring, MD: US Department of Health and Human Ser vices; 2012. http://www.fda.gov/Drugs/ DrugSafety/ucm293101.htm. July 7, 2012. Accessed April 2, 2015.

^{‹‹88››.} Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4): 549–57.

^{‹‹89››.} Grant WB. Dietary links to Alzheimer’s disease. Alzheimer Dis Rev. 1997;2:42–55.

^{‹‹90››.} Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer’s disease in a rural community in India: the Indo-US study. Neurology. 2001;57(6):985–9.

^{‹‹91››.} White L, Petrovitch H, Ross GW, et al. Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia aging study. JAMA. 1996;276(12):955–60.

^{‹‹92››.} Grant WB. Dietary links to Alzheimer’s disease. Alzheimer Dis Rev. 1997;2:42–55.

^{‹‹93››.} Grant WB. Trends in diet and Alzheimer’s disease during the nutrition transition in Japan and developing countries. J Alzheimers Dis. 2014;38(3):611–20.

^{‹‹94››.} Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990–2010: A systematic review and analysis. Lancet. 2013;381(9882): 2016–23.

^{‹‹95››.} Grant WB. Trends in diet and Alzheimer’s disease during the nutrition transition in Japan and developing countries. J Alzheimers Dis. 2014;38(3):611–20.

^{‹‹96››.} Chandra V, Ganguli M, Pandav R, et al. Prevalence of Alzheimer’s disease and other dementias in rural India: the Indo-US study. Neurology. 1998;51(4):1000–8.

^{‹‹97››.} Shetty PS. Nutrition transition in India. Public Health Nutr. 2002;5(1A):175–82.

^{‹‹98››.} Giem P, Beeson WL, Fraser GE. The incidence of dementia and intake of animal products: preliminary findings from the Adventist Health Study. Neuroepidemiology. 1993;12(1):28–36.

^{‹‹99››.} Roses AD, Saunders AM. APOE is a major susceptibility gene for Alzheimer’s disease. Curr Opin Biotechnol. 1994;5(6):663–7.

^{‹‹100››.} Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci. 2003;6(4):345–51.

^{‹‹101››.} Chen X, Hui L, Soliman ML, Geiger JD. Altered cholesterol intracellular trafficking and the development of pathological hallmarks of sporadic AD. J Parkinsons Dis Alzheimers Dis. 2014;1(1).

^{‹‹102››.} Sepehrnia B, Kamboh MI, Adams-Campbell LL, et al. Genetic studies of human apolipoproteins.X. The effect of the apolipoprotein E polymorphism on quantitative levels of lipoproteins in Nigerian blacks. Am J Hum Genet. 1989;45(4):586–91.

^{‹‹103››.} Grant WB. Dietary links to Alzheimer’s disease. Alzheimer Dis Rev. 1997;2:42–55.

^{‹‹104››.} Sepehrnia B, Kamboh MI, Adams-Campbell LL, et al. Genetic studies of human apolipoproteins. X. The Effect of the apolipoprotein E polymorphism on quantitative levels of lipoproteins in Nigerian blacks. Am J Hum Genet. 1989;45(4):586–91.

^{‹‹105››.} Hendrie HC, Murrell J, Gao S, Unverzagt FW, Ogunniyi A, Hall KS. International studies in dementia with particular emphasis on populations of African origin. Alzheimer Dis Assoc Disord. 2006;20(3 Suppl 2):S42–6.

^{‹‹106››.} Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149–55.

^{‹‹107››.} Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149–55.

^{‹‹108››.} Jost BC, Grossberg GT. The natural history of Alzheimer’s disease: a brain bank study. J Am Geriatr Soc. 1995;43(11):1248–55.

^{‹‹109››.} Del Tredici K, Braak H. Neurofi brillary changes of the Alzheimer type in very elderly individuals: neither inevitable nor benign: Commentary on ‘No disease in the brain of a 115-year-old woman.’ Neurobiol Aging. 2008;29(8):1133–6.

^{‹‹110››.} Barnard ND, Bush AI, Ceccarelli A, et al. Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol Aging. 2014;35 Suppl 2:S74–8.

^{‹‹111››.} Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology. 2013;24(4):479–89.

^{‹‹112››.} Roberts RO, Geda YE, Cerhan JR, et al. Vegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairment. Dementia and Geriatric Cognitive Disorders. 2010;29(5):413–23.

^{‹‹113››.} Okereke OI, Rosner BA, Kim DH, et al. Dietary fat types and 4-year cognitive change in community- dwelling older women. Ann Neurol. 2012;72(1):124–34.

^{‹‹114››.} Parletta N, Milte CM, Meyer BJ. Nutritional modulation of cognitive function and mental health. J Nutr Biochem. 2013;24(5):725–43.

^{‹‹115››.} Essa MM, Vijayan RK, Castellano-Gonzalez G, Memon MA, Braidy N, Guillemin GJ. Neuroprotective effect of natural products against Alzheimer’s disease. Neurochem Res. 2012; 37(9):1829–42.

^{‹‹116››.} Shukitt-Hale B. Blueberries and neuronal aging. Gerontology. 2012;58(6):518–23.

^{‹‹117››.} Cherniack EP. A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders. Br J Nutr. 2012;108(5):794–800.

^{‹‹118››.} Johnson EJ. A possible role for lutein and zeaxanthin in cognitive function in the elderly. Am J Clin Nutr. 2012;96(5):1161S–5S.

^{‹‹119››.} Krikorian R, Shidler MD, Nash TA, et al. Blueberry supplementation improves memory in older adults. J Agric Food Chem. 2010;58(7):3996–4000.

^{‹‹120››.} Devore EE, Kang JH, Breteler MMB, et al. Dietary intakes of berries and flavonoids in relation to cognitive decline. Ann Neurol. 2012;72(1):135–43.

^{‹‹121››.} Dai Q, Borenstein AR, Wu Y, et al. Fruit and vegetable juices and Alzheimer’s disease: the Kame Project. Am J Med. 2006;119(9):751–9.

^{‹‹122››.} Krikorian R, Nash TA, Shidler MD, Shukitt-Hale B, Joseph JA. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br J Nutr. 2010;103(5):730–4.

^{‹‹123››.} Nurk E, Refsum H, Drevon CA, et al. Cognitive performance among the elderly in relation to the intake of plant foods. The Hordaland Health Study. Br J Nutr. 2010;104(8):1190–201.

^{‹‹124››.} Mullen W, Marks SC, Crozier A. Evaluation of phenolic compounds in commercial fruit juices and fruit drinks. J Agric Food Chem. 2007;55(8):3148–57.

^{‹‹125››.} Tarozzi A, Morroni F, Merlicco A, et al. Neuroprotective Effects of cyanidin 3-O-glucopyranoside on amyloid beta (25–35) oligomer-induced toxicity. Neurosci Lett. 2010;473(2):72–6.

^{‹‹126››.} Hattori M, Sugino E, Minoura K, et al. Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain. Biochem Biophys Res Commun. 2008;374(1):158–63.

^{‹‹127››.} Mandel SA, Weinreb O, Amit T, Youdim MB. Molecular mechanisms of the neuroprotective/neurorescue action of multi-target green tea polyphenols. Front Biosci (Schol Ed). 2012; 4:581–98.

^{‹‹128››.} Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045–60.

^{‹‹129››.} Hishikawa N, Takahashi Y, Amakusa Y, et al. Effects of turmeric on Alzheimer’s disease with behavioral and psychological symptoms of dementia. Ayu. 2012;33(4):499–504.

^{‹‹130››.} Akhondzadeh S, Sabet MS, Harirchian MH, et al. Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther. 2010;35(5):581–8.

^{‹‹131››.} Akhondzadeh S, Shafiee Sabet M, Harirchian MH, et al. A 22-week, multicenter, randomized, double- blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease. Psychopharmacology (Berl). 2010;207(4):637–43.

^{‹‹132››.} Hyde C, Peters J, Bond M, et al. Evolution of the evidence on the Effectiveness and costeffectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model. Age Ageing. 2013;42(1):14–20.

^{‹‹133››.} US Food and Drug Administation. ARICEPT® (Donepezil Hydrochloride Tablets) package insert. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/DrugM arketingAdvertisingandCommunications/UCM368444.pdf. Accessed April 2, 2015.

^{‹‹134››.} Toledo C, Saltsman K. Genetics by the Numbers. Inside Life Science, Bethesda, MD: National Institute of General Medical Sciences. http://publications.nigms. nih.gov/insidelifescience/genetics-numbers.html. June 11, 2012. Accessed March 3, 2015.

^{‹‹135››.} Mostoslavsky R, Esteller M, Vaquero A. At the crossroad of lifespan, calorie restriction, chromatin and disease: meeting on sirtuins. Cell Cycle. 2010;9(10):1907–12.

^{‹‹136››.} Julien C, Tremblay C, Emond V, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol. 2009;68(1):48–58.

^{‹‹137››.} Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci USA. 2014;111(13):4940–5.

^{‹‹138››.} Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci USA. 2014;111(13):4940–5.

^{‹‹139››.} Rahmadi A, Steiner N, Munch G. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer’s disease. Clin Chem Lab Med. 2011;49(3):385–91.

^{‹‹140››.} Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci. 2010;65(9):963–75.

^{‹‹141››.} Srikanth V, Westcott B, Forbes J, et al. Methylglyoxal, cognitive function and cerebral atrophy in older people. J Gerontol A Biol Sci Med Sci. 2013;68(1):68–73.

^{‹‹142››.} Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci USA. 2014;111(13):4940–5.

^{‹‹143››.} Beeri MS, Moshier E, Schmeidler J, et al. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev. 2011;132(11–12):583–7.

^{‹‹144››.} Yaffe K, Lindquist K, Schwartz AV, et al. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology. 2011;77(14):1351–6.

^{‹‹145››.} Angeloni C, Zambonin L, Hrelia S. Role of methylglyoxal in Alzheimer’s disease. Biomed Res Int. 2014;2014:238485.

^{‹‹146››.} Vlassara H, Cai W, Goodman S, et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab. 2009;94(11):4483–91.

^{‹‹147››.} Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA. 1997;94(25):13915–20.

^{‹‹148››.} Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci. 2005;1043:461–6.

^{‹‹149››.} Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci. 2005;1043:461–6.

^{‹‹150››.} Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911–6.e12.

^{‹‹151››.} Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911–6.e12.

^{‹‹152››.} Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911–6.e12.

^{‹‹153››.} Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci USA. 2014;111(13):4940–5.

^{‹‹154››.} Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol. 2010;67(1):71–9.

^{‹‹155››.} Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol. 2010;67(1):71–9.

^{‹‹156››.} Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108(7):3017–22.

^{‹‹157››.} ten Brinke LF, Bolandzadeh N, Nagamatsu LS, et al. Aerobic exercise increases hippocampal volume in older women with probable mild cognitive impairment: a 6-month randomised controlled trial. Br J Sports Med. 2015;49(4):248–54.